CHDI
Listed here are over 1000 publications that describe some of the research funded (in whole or in part) by CHDI Foundation. You can also view just the subset of publications that have CHDI staff as authors.
Publication Search
Title
Journal
Kraft AD, Kaltenbach LS, Lo DC, Harry GJ
Activated microglia proliferate at neurites of mutant huntingtin-expressing neurons
Baldo B, Paganetti P, Grueninger S, Marcellin D, Kaltenbach LS, Lo DC, Semmelroth M, Zivanovic A, Abramowski D, Smith D, Lotz GP, Bates GP, Weiss A
TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington's disease
Dorsey E, Huntington Study Group COHORT Investigators
Characterization of a large group of individuals with Huntington disease and their relatives enrolled in the COHORT study
Beconi MG, Howland D, Park L, Lyons K, Giuliano J, Dominguez C, Munoz-Sanjuan I, Pacifici R
Pharmacokinetics of memantine in rats and mice
Menalled L, El-Khodor BF, Hornberger M, Park L, Howland D, Brunner D
Effect of the rd1 mutation on motor performance in R6/2 and wild type mice
Prime ME, Andersen OA, Barker JJ, Brooks MA, Cheng RK, Toogood-Johnson I, Courtney SM, Brookfield FA, Yarnold CJ, Marston RW, Johnson PD, Johnsen SF, Palfrey JJ, Vaidya D, Erfan S, Ichihara O, Felicetti B, Palan S, Pedret-Dunn A, Schaertl S, Sternberger I, Ebneth A, Scheel A, Winkler D, Toledo-Sherman L, Beconi M, Macdonald D, Munoz-Sanjuan I, Dominguez C, Wityak J
Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington`s disease
Zeef DH, van Goethem NP, Vlamings R, Schaper F, Jahanshahi A, Hescham S, von Hörsten S, Prickaerts J, Temel Y
Memory deficits in the transgenic rat model of Huntington's disease
Zeef DH, Vlamings R, Lim LW, Tan S, Janssen ML, Jahanshahi A, Hoogland G, Prickaerts J, Steinbusch HW, Temel Y
Motor and non-motor behaviour in experimental Huntington's disease
Neveklovska M, Clabough EB, Steffan JS, Zeitlin SO
Deletion of the huntingtin proline-rich region does not significantly affect normal huntingtin function in mice
Cuesta M, Aungier J, Morton AJ
The methamphetamine-sensitive circadian oscillator is dysfunctional in a transgenic mouse model of Huntington's disease
Sarantos MR, Papanikolaou T, Ellerby LM, Hughes RE
Pizotifen activates ERK and provides neuroprotection in vitro and in vivo in models of Huntington's disease
J Huntingtons Dis
January 1, 2012
1 (2) :195-210
1 (2) :195-210
PMID: 23393546
PMCID: 3564659
DOI: 10.3233/JHD-120033
Sontag EM, Lotz GP, Yang G, Sontag CJ, Cummings BJ, Glabe CG, Muchowski PJ, Thompson LM
Detection of mutant huntingtin aggregation conformers and modulation of SDS-soluble fibrillar oligomers by small molecules
Galvan L, Andre VM, Wang EA, Cepeda C, Levine MS
Functional differences between direct and indirect striatal output pathways in Huntington`s disease
Oakeshott S, Port R, Cummins-Sutphen J, Berger J, Watson-Johnson J, Ramboz S, Paterson N, Kwak S, Howland D, Brunner D
A mixed fixed ratio/progressive ratio procedure reveals an apathy phenotype in the BAC HD and the z_Q175 KI mouse models of Huntington`s disease
Heikkinen T, Lehtimaki K, Vartiainen N, Puolivali J, Hendricks SJ, Glaser JR, Bradaia A, Wadel K, Touller C, Kontkanen O, Yrjanheikki JM, Buisson B, Howland D, Beaumont V, Munoz-Sanjuan I, Park LC
Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington`s disease
Menalled LB, Kudwa AE, Miller S, Fitzpatrick J, Watson-Johnson J, Keating N, Ruiz M, Mushlin R, Alosio W, McConnell K, Connor D, Murphy C, Oakeshott S, Kwan M, Beltran J, Ghavami A, Brunner D, Park LC, Ramboz S, Howland D
Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington`s disease: zQ175
Beconi M, Aziz O, Matthews K, Moumne L, O`Connell C, Yates D, Clifton S, Pett H, Vann J, Crowley L, Haughan AF, Smith DL, Woodman B, Bates GP, Brookfield F, Burli RW, McAllister G, Dominguez C, Munoz-Sanjuan I, Beaumont V
Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo
Tabrizi SJ, Reilmann R, Roos RAC, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR
Potential endpoints for clinical trials in premanifest and early Huntington`s disease in the TRACK-HD study: analysis of 24 month observational data
The Lancet Neurology
January 1, 2012
11 (1) :42-53
11 (1) :42-53
PMID: 22137354
Quarrell OW, Handley O, O`Donovan K, Dumoulin C, Ramos-Arroyo M, Biunno I, Bauer P, Kline M, Landwehrmeyer GB, European Huntington`s Disease Network
Discrepancies in reporting the CAG repeat lengths for Huntington`s disease
Raymond LA, André VM, Cepeda C, Gladding CM, Milnerwood AJ, Levine MS
Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function
Cowin RM, Bui N, Graham D, Green JR, Grueninger S, Yuva-Paylor LA, Syed AU, Weiss A, Paylor R
Onset and progression of behavioral and molecular phenotypes in a novel congenic R6/2 line exhibiting intergenerational CAG repeat stability
Zhang Y, Long JD, Mills JA, Warner JH, Lu W, Paulsen JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group
Indexing disease progression at study entry with individuals at-risk for Huntington disease
Am J Med Genet B Neuropsychiatr Genet
December 2, 2011
156B (7) :751-63
156B (7) :751-63
PMID: 21858921
PMCID: 3174494
DOI: 10.1002/ajmg.b.31232
Majid DS, Aron AR, Thompson W, Sheldon S, Hamza S, Stoffers D, Holland D, Goldstein J, Corey-Bloom J, Dale AM
Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation
Paulsen JS
Cognitive impairment in Huntington disease: diagnosis and treatment
van der Burg JM, Winqvist A, Aziz NA, Maat-Schieman ML, Roos RA, Bates GP, Brundin P, Björkqvist M, Wierup N
Gastrointestinal dysfunction contributes to weight loss in Huntington's disease mice
Benraiss A, Goldman SA
Cellular therapy and induced neuronal replacement for Huntington's disease
Maillard MC, Brookfield FA, Courtney SM, Eustache FM, Gemkow MJ, Handel RK, Johnson LC, Johnson PD, Kerry MA, Krieger F, Meniconi M, Munoz-Sanjuan I, Palfrey JJ, Park H, Schaertl S, Taylor MG, Weddell D, Dominguez C
Exploiting differences in caspase-2 and -3 S(2) subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors
Muller I, Lamers MB, Ritchie AJ, Dominguez C, Munoz-Sanjuan I, Kiselyov A
Structure of human caspase-6 in complex with Z-VAD-FMK: New peptide binding mode observed for the non-canonical caspase conformation
Bioorg Med Chem Lett
September 15, 2011
21 (18) :5244-7
21 (18) :5244-7
PMID: 21820899
Valenza M, Cattaneo E
Emerging roles for cholesterol in Huntington's disease
Huang K, Sanders SS, Kang R, Carroll JB, Sutton L, Wan J, Singaraja R, Young FB, Liu L, El-Husseini A, Davis NG, Hayden MR
Wild-type HTT modulates the enzymatic activity of the neuronal palmitoyl transferase HIP14
Hum Mol Genet
September 1, 2011
20 (17) :3356-65
20 (17) :3356-65
PMID: 21636527
PMCID: PMC3153302
DOI: 10.1093/hmg/ddr242
Carroll JB, Southwell AL, Graham RK, Lerch JP, Ehrnhoefer DE, Cao LP, Zhang WN, Deng Y, Bissada N, Henkelman RM, Hayden MR
Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease
Wetzel HH, Gehl CR, Dellefave-Castillo L, Schiffman JF, Shannon KM, Paulsen JS, Huntington Study Group
Suicidal ideation in Huntington disease: the role of comorbidity
van den Bogaard SJ, Dumas EM, Ferrarini L, Milles J, van Buchem MA, van der Grond J, Roos RA
Shape analysis of subcortical nuclei in Huntington`s disease, global versus local atrophy--results from the TRACK-HD study
Zuccato C, Marullo M, Vitali B, Tarditi A, Mariotti C, Valenza M, Lahiri N, Wild EJ, Sassone J, Ciammola A, Bachoud-Lèvi AC, Tabrizi SJ, Di Donato S, Cattaneo E
Brain-derived neurotrophic factor in patients with Huntington's disease
Williams J, Downing N, Vaccarino AL, Guttman M, Paulsen JS
Self reports of day-to-day function in a small cohort of people with prodromal and early HD
Hobbs NZ, Pedrick AV, Say MJ, Frost C, Dar Santos R, Coleman A, Sturrock A, Craufurd D, Stout JC, Leavitt BR, Barnes J, Tabrizi SJ, Scahill RI
The structural involvement of the cingulate cortex in premanifest and early Huntington`s disease
Ready RE, O’Rourke JJ, Paulsen JS
Quality of life in prodromal HD: Qualitative analyses of discourse from participants and companions
Muller I, Lamers MB, Ritchie AJ, Park H, Dominguez C, Munoz-Sanjuan I, Maillard M, Kiselyov A
A new apo-caspase-6 crystal form reveals the active conformation of the apoenzyme
Reinhart PH, Kaltenbach LS, Essrich C, Dunn DE, Eudailey JA, DeMarco CT, Turmel GJ, Whaley JC, Wood A, Cho S, Lo DC
Identification of anti-inflammatory targets for Huntington's disease using a brain slice-based screening assay